# Lineage Cell Therapeutics, Inc. (LCTX) · Edgar & Edgarette company card

> Lineage Cell Therapeutics (LCTX) grew revenue 53.2% in FY2025 to $15 million, operating margin -252% against a -15.8% median for biological products, (no diagnostic substances), equity 39.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 876343 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/LCTX) · [JSON](https://www.pops4.com/boards/company/LCTX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $15M |
| Revenue growth, 1 year | 53.2% |
| Revenue growth per year | 35.3% |
| Operating margin | -251.6% (prior year -226.1%) |
| Net margin | -436.5% |
| Operating cash flow | −$19M |
| Capital spending | $522,000 |
| Free cash flow | −$19M |
| Cash | $41M |
| Long-term debt | — |
| Total assets | $113M |
| Total equity | $45M |
| Equity ÷ assets | 39.6% |
| Return on equity | -142.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -12.25 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -251.6% in FY2025; revenue is hard to predict: its 80% range is ±83%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $14.6M (FY2025). Experience: revenue up 53.2% on the year, up 35.3% a year over 4 years; operating margin -251.6%, down from -226.1%. Soundness: equity 39.6% of assets, return on equity -142.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.5M and $60.8M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $4.7M to $72.1M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -251.6% against a -15.8% median; growth 53.2% against 21.4%.

Range logged 2026-11-01, receipt 14d5358fdcf028b6, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/876343/000119312526458487/0001193125-26-458487-index.htm)
- 8-K · filed 2026-11-12 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.02 Results of Operations and Financial Condition; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/876343/000119312526458377/0001193125-26-458377-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/876343/000119312526338064/0001193125-26-338064-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/0001193125-26-338020-index.htm)
- 8-K · filed 2026-06-12 · 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm)
- 10-Q · filed 2026-05-12 · [filing](https://www.sec.gov/Archives/edgar/data/876343/000119312526219479/0001193125-26-219479-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000876343.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=876343

## Cite

POPS4, Edgar & Edgarette: Lineage Cell Therapeutics, Inc. (LCTX) company card, from the company's own SEC filings, accessed 2026-11-13, https://www.pops4.com/boards/company/LCTX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.